Newer therapies for asthma: a focus on anti-IgE
Newer therapies for asthma: a focus on anti-IgE
The prevalence of asthma and other allergic disorders has been on the increase not only in the western world but also in the developing countries. This increasing prevalence has lead research into the discovery and development of various new therapeutic strategies. The improved understanding about the pathophysiology of asthma has prompted the developments of novel molecules to tackle this problem. These include newer phosphodiesterase inhibitors, cytokine modulation strategies, allergen immunotherapy, and anti-IgE.
Immunoglobulin E plays a major role in airway inflammation in asthma. Omalizumab, a novel humanised monoclonal antibody directed against the high affinity FcepsilonRI portion of the IgE has shown a lot of promise in the control of asthma symptoms and as a steroid sparing agent in the management of allergic asthma. This new molecule has an excellent safety profile and could play an important role in the management of patients with severe asthma. This review gives a brief overview of the newer therapies under investigation with special reference to omalizumab in the treatment of allergic asthma.
asthma, di, th, prevalence, hypersensitivity, receptors, ige, dt, drug evaluation, human
107-115
Babu, K.S.
b21f201e-3285-4943-9347-a1a3c8727a00
Holgate, S.T.
2e7c17a9-6796-436e-8772-1fe6d2ac5edc
2002
Babu, K.S.
b21f201e-3285-4943-9347-a1a3c8727a00
Holgate, S.T.
2e7c17a9-6796-436e-8772-1fe6d2ac5edc
Babu, K.S. and Holgate, S.T.
(2002)
Newer therapies for asthma: a focus on anti-IgE.
The Indian Journal of Chest Diseases & Allied Sciences, 44 (2), .
Abstract
The prevalence of asthma and other allergic disorders has been on the increase not only in the western world but also in the developing countries. This increasing prevalence has lead research into the discovery and development of various new therapeutic strategies. The improved understanding about the pathophysiology of asthma has prompted the developments of novel molecules to tackle this problem. These include newer phosphodiesterase inhibitors, cytokine modulation strategies, allergen immunotherapy, and anti-IgE.
Immunoglobulin E plays a major role in airway inflammation in asthma. Omalizumab, a novel humanised monoclonal antibody directed against the high affinity FcepsilonRI portion of the IgE has shown a lot of promise in the control of asthma symptoms and as a steroid sparing agent in the management of allergic asthma. This new molecule has an excellent safety profile and could play an important role in the management of patients with severe asthma. This review gives a brief overview of the newer therapies under investigation with special reference to omalizumab in the treatment of allergic asthma.
This record has no associated files available for download.
More information
Published date: 2002
Keywords:
asthma, di, th, prevalence, hypersensitivity, receptors, ige, dt, drug evaluation, human
Identifiers
Local EPrints ID: 26917
URI: http://eprints.soton.ac.uk/id/eprint/26917
ISSN: 0377-9343
PURE UUID: 0a20cd2a-da97-4ee8-897b-e25bf5a2bfd2
Catalogue record
Date deposited: 25 Apr 2006
Last modified: 08 Jan 2022 06:51
Export record
Contributors
Author:
K.S. Babu
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics